January 23, 2024
CSL Behring said on January 22 that it has obtained approval for prefilled syringe versions of its immunoglobulin agent Hizentra in Japan. The approval was granted on January 17 for three prefilled syringe dosages (1 g/5 mL, 2 g/10 mL,...read more